Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease
Authors not listed
reMYND · 2022
Abstract
The purpose of this study is to measure effects on CSF biomarkers, EEG and safety with REM0046127 oral suspension compared with placebo in subjects with mild to moderate Alzheimer disease.
* The study duration will be up to 2 months for each treated subject
* Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period
* Visit frequency: every week
* Number of Subjects: at least 30 subjects with an upper limit of 60 subjects.
* Study Arms and Duration: All subjects will be randomized (1:1:1 allocation) to one ofthree different starting levels after the 14-day run-in period:
* REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days
* REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days
* Placebo: placebo oral suspension bid for 28 days
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2022). A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease. <em>reMYND</em>. https://clinicaltrials.gov/study/NCT05478031
Vancouver
Anonymous. A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease. reMYND. 2022.
BibTeX
@misc{anon2022ARando,
title = {A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease},
author = {Anonymous},
journal = {reMYND},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Pfizer 2009
Open access · US-GOV
A PHASE 2 MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE
Kieu Dang Phuong Nguyen 2025
Open access · US-GOV
Effects of Resistance Training on Sarcopenia in Older Patients With Chronic Heart Failure: A Randomized Controlled Trial
Memory Pharmaceuticals 2007
Open access · US-GOV
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease
Neuronix Ltd 2010
Open access · US-GOV
Effects of a Combined TMS Stimulation and Cognitive Training in Alzheimer Patients: a Single-center, Randomized, Double-blind, Placebo-controlled Study
The Cleveland Clinic 2009
Open access · US-GOV
Neural Effects of Exercise, Cognitive, or Combined Training in AD At-Risk Elders
Free Radical Biology and Medicine 2016
Preprint · OA